Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity

James Turkson, Joon S. Kim, Shumin Zhang, Jing Yuan, Mei Huang, Matthew Glenn, Eric Haura, Said Sebti, Andrew Hamilton, Richard Jove

Research output: Contribution to journalArticle

Abstract

The critical role of signal transducer and activator of transcription 3 (Stat3) in the growth and survival of human tumor cells identifies it as a promising target for cancer drug discovery. We previously identified a Stat3 SH2 domain-binding phosphopeptide, PYLKTK, and its tripeptide derivatives, PYL and AYL (where Y represents phosphotyrosine), which inhibit Stat3 biochemical activity and biological function. Here, we report novel peptidomimetic compounds based on PYL (or AYL) with substitution of the Y-1 residue by benzyl, pyridyl, or pyrazinyl derivatives that are selective and greater than 5-fold more potent in disrupting Stat3 activity in vitro than lead tripeptides. The biological activities of these derivatives mirror that originally observed for peptides. In this context, the representative peptidomimetic ISS 610 with 4-cyanobenzoate substitution inhibits constitutive Stat3 activity in Src-transformed mouse fibroblasts and human breast and lung carcinoma cells. This effect is not evident with the non-phosphorylated counterpart, ISS 610NP, consistent with interaction of peptidomimetics with the SH2 domain of Stat3. Moreover, ISS 610 induces cell growth inhibition and apoptosis of Src-transformed fibroblasts that contain persistently active Stat3. We present the first report of a peptidomimetic approach to design of small-molecule inhibitors of Stat3 that are also among the first examples of disruptors; of transcription factor dimerization with the potential for novel cancer therapy.

Original languageEnglish (US)
Pages (from-to)261-269
Number of pages9
JournalMolecular Cancer Therapeutics
Volume3
Issue number3
StatePublished - Mar 2004

Fingerprint

Peptidomimetics
STAT3 Transcription Factor
Dimerization
src Homology Domains
Fibroblasts
Phosphopeptides
Neoplasms
Phosphotyrosine
Drug Discovery
Growth
Transcription Factors
Apoptosis
Breast Neoplasms
Lung
Peptides
Survival

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., ... Jove, R. (2004). Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Molecular Cancer Therapeutics, 3(3), 261-269.

Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. / Turkson, James; Kim, Joon S.; Zhang, Shumin; Yuan, Jing; Huang, Mei; Glenn, Matthew; Haura, Eric; Sebti, Said; Hamilton, Andrew; Jove, Richard.

In: Molecular Cancer Therapeutics, Vol. 3, No. 3, 03.2004, p. 261-269.

Research output: Contribution to journalArticle

Turkson, J, Kim, JS, Zhang, S, Yuan, J, Huang, M, Glenn, M, Haura, E, Sebti, S, Hamilton, A & Jove, R 2004, 'Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity', Molecular Cancer Therapeutics, vol. 3, no. 3, pp. 261-269.
Turkson, James ; Kim, Joon S. ; Zhang, Shumin ; Yuan, Jing ; Huang, Mei ; Glenn, Matthew ; Haura, Eric ; Sebti, Said ; Hamilton, Andrew ; Jove, Richard. / Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. In: Molecular Cancer Therapeutics. 2004 ; Vol. 3, No. 3. pp. 261-269.
@article{12f6a6d9e57f4115bba0cd1735a2a3fb,
title = "Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity",
abstract = "The critical role of signal transducer and activator of transcription 3 (Stat3) in the growth and survival of human tumor cells identifies it as a promising target for cancer drug discovery. We previously identified a Stat3 SH2 domain-binding phosphopeptide, PYLKTK, and its tripeptide derivatives, PYL and AYL (where Y represents phosphotyrosine), which inhibit Stat3 biochemical activity and biological function. Here, we report novel peptidomimetic compounds based on PYL (or AYL) with substitution of the Y-1 residue by benzyl, pyridyl, or pyrazinyl derivatives that are selective and greater than 5-fold more potent in disrupting Stat3 activity in vitro than lead tripeptides. The biological activities of these derivatives mirror that originally observed for peptides. In this context, the representative peptidomimetic ISS 610 with 4-cyanobenzoate substitution inhibits constitutive Stat3 activity in Src-transformed mouse fibroblasts and human breast and lung carcinoma cells. This effect is not evident with the non-phosphorylated counterpart, ISS 610NP, consistent with interaction of peptidomimetics with the SH2 domain of Stat3. Moreover, ISS 610 induces cell growth inhibition and apoptosis of Src-transformed fibroblasts that contain persistently active Stat3. We present the first report of a peptidomimetic approach to design of small-molecule inhibitors of Stat3 that are also among the first examples of disruptors; of transcription factor dimerization with the potential for novel cancer therapy.",
author = "James Turkson and Kim, {Joon S.} and Shumin Zhang and Jing Yuan and Mei Huang and Matthew Glenn and Eric Haura and Said Sebti and Andrew Hamilton and Richard Jove",
year = "2004",
month = "3",
language = "English (US)",
volume = "3",
pages = "261--269",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity

AU - Turkson, James

AU - Kim, Joon S.

AU - Zhang, Shumin

AU - Yuan, Jing

AU - Huang, Mei

AU - Glenn, Matthew

AU - Haura, Eric

AU - Sebti, Said

AU - Hamilton, Andrew

AU - Jove, Richard

PY - 2004/3

Y1 - 2004/3

N2 - The critical role of signal transducer and activator of transcription 3 (Stat3) in the growth and survival of human tumor cells identifies it as a promising target for cancer drug discovery. We previously identified a Stat3 SH2 domain-binding phosphopeptide, PYLKTK, and its tripeptide derivatives, PYL and AYL (where Y represents phosphotyrosine), which inhibit Stat3 biochemical activity and biological function. Here, we report novel peptidomimetic compounds based on PYL (or AYL) with substitution of the Y-1 residue by benzyl, pyridyl, or pyrazinyl derivatives that are selective and greater than 5-fold more potent in disrupting Stat3 activity in vitro than lead tripeptides. The biological activities of these derivatives mirror that originally observed for peptides. In this context, the representative peptidomimetic ISS 610 with 4-cyanobenzoate substitution inhibits constitutive Stat3 activity in Src-transformed mouse fibroblasts and human breast and lung carcinoma cells. This effect is not evident with the non-phosphorylated counterpart, ISS 610NP, consistent with interaction of peptidomimetics with the SH2 domain of Stat3. Moreover, ISS 610 induces cell growth inhibition and apoptosis of Src-transformed fibroblasts that contain persistently active Stat3. We present the first report of a peptidomimetic approach to design of small-molecule inhibitors of Stat3 that are also among the first examples of disruptors; of transcription factor dimerization with the potential for novel cancer therapy.

AB - The critical role of signal transducer and activator of transcription 3 (Stat3) in the growth and survival of human tumor cells identifies it as a promising target for cancer drug discovery. We previously identified a Stat3 SH2 domain-binding phosphopeptide, PYLKTK, and its tripeptide derivatives, PYL and AYL (where Y represents phosphotyrosine), which inhibit Stat3 biochemical activity and biological function. Here, we report novel peptidomimetic compounds based on PYL (or AYL) with substitution of the Y-1 residue by benzyl, pyridyl, or pyrazinyl derivatives that are selective and greater than 5-fold more potent in disrupting Stat3 activity in vitro than lead tripeptides. The biological activities of these derivatives mirror that originally observed for peptides. In this context, the representative peptidomimetic ISS 610 with 4-cyanobenzoate substitution inhibits constitutive Stat3 activity in Src-transformed mouse fibroblasts and human breast and lung carcinoma cells. This effect is not evident with the non-phosphorylated counterpart, ISS 610NP, consistent with interaction of peptidomimetics with the SH2 domain of Stat3. Moreover, ISS 610 induces cell growth inhibition and apoptosis of Src-transformed fibroblasts that contain persistently active Stat3. We present the first report of a peptidomimetic approach to design of small-molecule inhibitors of Stat3 that are also among the first examples of disruptors; of transcription factor dimerization with the potential for novel cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=3543055012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543055012&partnerID=8YFLogxK

M3 - Article

C2 - 15026546

AN - SCOPUS:3543055012

VL - 3

SP - 261

EP - 269

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -